BUZZ-Silexion Therapeutics falls after $5 mln public offering

Reuters

16 Jan

BUZZ-Silexion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> falls after $5 mln public offering

** Shares of drug developer Silexion Therapeutics SLXN.O fall 28.2% to $1.12

** SLXN says it is raising $5 mln through a public offering

** Public offering price is $1.35/share; 13.5% discount to the stock's last close

** Company plans to sue the proceeds to advance pre-clinical studies and for general corporate purposes

** H.C. Wainwright & Co. is the exclusive placement agent for the offering

** SLXN fell 88.3% in 2024 since its Nasdaq debut on Aug. 16, 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503919160"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503919160\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503919160?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-16 23:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503919160","market":"us","top_or_hot":-1,"title":"BUZZ-Silexion Therapeutics falls after $5 mln public offering","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Silexion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> falls after $5 mln public offering</title></head><body><p>** Shares of drug developer Silexion Therapeutics <span>SLXN.O</span> fall 28.2% to $1.12 </p><p>** SLXN <span>says</span> it is raising $5 mln through a public offering</p><p>** Public offering price is $1.35/share; 13.5% discount to the stock's last close</p><p>** Company plans to sue the proceeds to advance pre-clinical studies and for general corporate purposes</p><p>** H.C. Wainwright &amp; Co. is the exclusive placement agent for the offering</p><p>** SLXN fell 88.3% in 2024 since its Nasdaq debut on Aug. 16, 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Silexion Therapeutics falls after $5 mln public offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Silexion Therapeutics falls after $5 mln public offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-16 23:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Silexion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> falls after $5 mln public offering</title></head><body><p>** Shares of drug developer Silexion Therapeutics <span>SLXN.O</span> fall 28.2% to $1.12 </p><p>** SLXN <span>says</span> it is raising $5 mln through a public offering</p><p>** Public offering price is $1.35/share; 13.5% discount to the stock's last close</p><p>** Company plans to sue the proceeds to advance pre-clinical studies and for general corporate purposes</p><p>** H.C. Wainwright &amp; Co. is the exclusive placement agent for the offering</p><p>** SLXN fell 88.3% in 2024 since its Nasdaq debut on Aug. 16, 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLXN","symbol_name":"Silexion Therapeutics Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250116:nL4N3OC1E9:1","article_id":"2503919160","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503919160","pubTimestamp":1737042153,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Silexion Therapeutics falls after $5 mln public offering** Shares of drug developer Silexion Therapeutics SLXN.O fall 28.2% to $1.12 ** SLXN says it is raising $5 mln through a public offering** Public offering price is $1.35/share; 13.5% discount to the stock's last close** Company plans to sue the proceeds to advance pre-clinical studies and for general corporate purposes** H.C. Wainwright & Co. is the exclusive placement agent for the offering** SLXN fell 88.3% in 2024 since its Nasdaq debut on Aug. 16, 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLXN":"Silexion Therapeutics Corp","BK4139":"生物科技"},"translate_title":"BUZZ-Silexion Therapeutics公开发行500万美元后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLXN":0.9},"content_text":"BUZZ-Silexion Therapeutics falls after $5 mln public offering** Shares of drug developer Silexion Therapeutics SLXN.O fall 28.2% to $1.12 ** SLXN says it is raising $5 mln through a public offering** Public offering price is $1.35/share; 13.5% discount to the stock's last close** Company plans to sue the proceeds to advance pre-clinical studies and for general corporate purposes** H.C. Wainwright & Co. is the exclusive placement agent for the offering** SLXN fell 88.3% in 2024 since its Nasdaq debut on Aug. 16, 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}